특수 효소 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, specialty enzymes market size in 2026 is estimated at USD 7.13 billion, growing from 2025 value of USD 6.59 billion with 2031 projections showing USD 10.52 billion, growing at 8.12% CAGR over 2026-2031.

This report is Segmented by Source (Plant, Microbial, and Animal), by Form (Liquid, and Dry), by Enzyme Type (Carbohydrases, Proteases, Lipases, and Others), by Application (Food and Beverages, Pharmaceutical, Animal Feed, and Others), and Geography (North America, Europe, Asia-Pacific, South America, and Middle East and Africa). The Market Forecasts are Provided in Terms of Value (USD).

Global Specialty Enzymes Market Trends and Insights

Increasing adoption of eco-friendly biocatalysts in pharmaceutical manufacturing

Pharmaceutical producers are increasingly replacing chemical catalysts with biocatalysts to reduce environmental impact and improve process efficiency. This shift is particularly valuable in biologics, where enzyme precision minimizes the need for complex purification steps. The Food and Drug Administration (FDA)'s regulatory review periods for biologics, including POMBILITI and EPKINLY in 2025, indicate streamlined approval processes for enzyme-based therapeutics . Engineered enzymes enable the production of chiral pharmaceutical intermediates with improved selectivity and reduced waste compared to traditional methods. Computational design tools have shortened enzyme development cycles, enabling pharmaceutical companies to develop biocatalysts for specific drug synthesis routes more efficiently. Enzyme applications now extend to advanced drug delivery systems and therapies for genetic disorders, broadening opportunities for manufacturers in the specialty enzyme space.

Government support drives market growth through policy and funding

Government initiatives are accelerating the growth of the specialty enzymes market through policy frameworks and direct funding that support research, commercialization, and industrial adoption. Governments are actively funding enzyme innovation through grants, tax benefits, and PPP collaborations that bridge academia and industry. India's BioE3 policy represents a major government intervention in biotechnology, with an allocation of INR 9,197 crore (USD 1.1 billion) to establish biomanufacturing hubs for bio-based chemicals and enzymes. The policy aims to achieve a USD 300 billion bioeconomy by 2030, identifying enzymes as essential components across six areas, including precision biotherapeutics and climate-resilient agriculture . China's updated food safety regulatory system has created opportunities for enzyme manufacturers through mandatory registration procedures that benefit established companies with proven safety records . The European Union's pre-market approval requirements for food enzymes have standardized safety assessments, reducing market entry barriers for compliant manufacturers.

High production cost for customized enzymes

The complex processes involved in designing, engineering, and scaling up tailored enzymes require substantial investment in advanced technologies, skilled labor, and quality control measures. The need for specialized raw materials and stringent regulatory compliance increases production costs. Tailoring enzymes for specialized industrial processes requires heavy research and developments investment, often taking two to three years before the product reaches commercial readiness. Small and medium-sized biotechnology companies encounter significant challenges in scaling production from laboratory to commercial quantities. The required fermentation infrastructure demands substantial capital investment and specialized expertise. The pricing difference between industrial and pharmaceutical enzymes reflects their distinct value propositions, with pharmaceutical proteins priced at higher end compared to industrial applications. Manufacturing economics are impacted by the requirement for specialized purification processes and quality control systems that comply with regulatory standards for different end-use applications.

Other drivers and restraints analyzed in the detailed report include:

1. Advancement in enzyme engineering and directed evolution
2. Demand from cosmetic and dermatology sectors for enzymatic peels
3. Short shelf life and stability challenges

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Microbial sources hold a 68.05% market share in 2025, due to the scalability and cost advantages of recombinant DNA technology for enzyme production. Plant-derived enzymes are growing at 9.35% CAGR (2026-2031), driven by consumer demand for natural ingredients and sustainability requirements in food and cosmetic applications. Animal-derived enzymes experience declining demand due to ethical concerns and regulatory restrictions, especially in European markets where alternative sources are increasingly required.

Microbial enzymes dominate because they can be produced under controlled fermentation conditions, ensuring consistent quality and minimizing contamination risks. Microbial production systems leverage advances in synthetic biology to develop production strains with improved enzyme secretion and minimized by-product formation. The growth in plant sources is supported by new enzyme extraction methods from agricultural waste, which create circular economy opportunities and lower raw material costs.

Liquid formulations dominate the market with a 56.60% share in 2025 and are projected to grow at a CAGR of 9.98% through 2031, driven by their superior performance characteristics and application versatility. Dry enzyme formulations maintain their position in specialized applications where extended shelf life and reduced shipping costs are essential, particularly in animal feed and industrial cleaning sectors. The market preference for liquid formulations stems from their immediate bioavailability and seamless integration into manufacturing processes without dissolution requirements. New stabilization technologies have helped extend the shelf life of liquid enzymes, overcoming one of their main historical drawbacks.

Non-aqueous liquid systems are increasing in adoption for applications that require better substrate solubility and reduced feedback inhibition. Concentrated liquid formulations offer reduced storage and transportation costs while maintaining enzyme activity. Dry formulations continue to improve through advanced spray-drying and freeze-drying techniques that maintain enzyme structure and activity during dehydration.

Complete Report Scope:

• By Source
  • Plant
  • Microbial
  • Animal
• By Form
  • Liquid
  • Dry
• By Type
  • Carbohydrases
  • Proteases
  • Lipases
  • Others
• By Application
  • Food and Beverages
  • Pharmaceutical
  • Animal Feed
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Netherlands
    • Italy
    • Sweden
    • Poland
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Singapore
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Chile
    • Colombia
    • Peru
    • Rest of South America
  • Middle East and Africa
    • United Arab Emirates
    • South Africa
    • Nigeria
    • Saudi Arabia
    • Egypt
    • Morocco
    • Turkey
    • Rest of Middle East and Africa

Geography Analysis

In 2025, North America clinched a commanding 32.78% share of the specialty enzymes market, supported by strong research and development capabilities and streamlined regulatory pathways for enzyme therapeutics. Leading universities in the region spearhead AI-driven enzyme design, propelling domestic innovation. Furthermore, tax incentives championing sustainable manufacturing have amplified enzyme utilization across various industrial processes, solidifying North America's preeminence. The region's strong focus on technological advancements and partnerships between academia and industry further strengthens its competitive edge in the global market.

Asia-Pacific is emerging as the fastest-growing region, driven by supportive government initiatives, cost advantages, and a skilled workforce, with a projected 9.62% CAGR. Supportive policies and inherent cost advantages underpin this growth. India's BioE3 strategy, coupled with China's revised food enzyme regulations, has smoothed the path for market entry. Moreover, the region's affordable production costs, a reservoir of skilled talent, and state-of-the-art infrastructure are luring global enzyme manufacturers. The region's growing focus on biotechnology and government-backed initiatives to enhance enzyme production capacity further contribute to its rapid growth.

Europe, South America, the Middle East, and the Africa region are also making strides. In Europe, strict safety standards and a sustainability-focused regulatory environment continue to foster innovation and consumer confidence. Additionally, the region's emphasis on green chemistry and eco-friendly enzyme applications aligns with its sustainability goals, driving further market expansion. Meanwhile, in South America, biotech ventures in Brazil and Argentina, buoyed by favorable trade agreements and bioeconomy initiatives, are driving growth in the food and agriculture sectors. The Middle East and Africa region is witnessing advancements, owing to healthcare enhancements and initiatives aimed at food security.

1. International Flavors & Fragrances
2. dsm-firmenich
3. Kerry Group plc
4. BASF SE
5. Associated British Foods plc
6. Amano Enzyme
7. Novozymes A/S
8. Specialty Enzymes & Probiotics
9. Suntaq International Limited
10. Biocatalysts Ltd.
11. Advanced Enzyme Technologies
12. ENZIQUIM
13. Nagase America LLC
14. AST Enzymes
15. Sunson Industry Group
16. Enzyme Development Corporation
17. Antozyme Biotech Pvt Ltd,
18. NOOR ENZYMES (DWC) LLC
19. Bioseutica BV
20. Apex International

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing adoption of eco-friendly biocatalysts in pharmaceutical manufacturing
  • 4.2.2 Government support drives market growth through policy and funding
  • 4.2.3 Advancement in enzyme engineering and directed evolution
  • 4.2.4 Demand from cosemetic and dermatology sectors for enzymatic peels
  • 4.2.5 Surge in demand for enzymatic wound debridement products
  • 4.2.6 Growing focus on green chemistry and sustainable industrial process
• 4.3 Market Restraints
  • 4.3.1 High production cost for customised enzymes
  • 4.3.2 Short shelf life and stability challenges
  • 4.3.3 Risk of allergic reaction and immunogenicity in enzyme therapy
  • 4.3.4 Ethical concern in use of animal-derived enzymes
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Outlook
• 4.6 Porter's Five Forces
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers/Consumers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Source
  • 5.1.1 Plant
  • 5.1.2 Microbial
  • 5.1.3 Animal
• 5.2 By Form
  • 5.2.1 Liquid
  • 5.2.2 Dry
• 5.3 By Type
  • 5.3.1 Carbohydrases
  • 5.3.2 Proteases
  • 5.3.3 Lipases
  • 5.3.4 Others
• 5.4 By Application
  • 5.4.1 Food and Beverages
  • 5.4.2 Pharmaceutical
  • 5.4.3 Animal Feed
  • 5.4.4 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.1.4 Rest of North America
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 France
    • 5.5.2.3 United Kingdom
    • 5.5.2.4 Spain
    • 5.5.2.5 Netherlands
    • 5.5.2.6 Italy
    • 5.5.2.7 Sweden
    • 5.5.2.8 Poland
    • 5.5.2.9 Belgium
    • 5.5.2.10 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Indonesia
    • 5.5.3.7 Thailand
    • 5.5.3.8 Singapore
    • 5.5.3.9 Rest of Asia-Pacific
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Chile
    • 5.5.4.4 Colombia
    • 5.5.4.5 Peru
    • 5.5.4.6 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 United Arab Emirates
    • 5.5.5.2 South Africa
    • 5.5.5.3 Nigeria
    • 5.5.5.4 Saudi Arabia
    • 5.5.5.5 Egypt
    • 5.5.5.6 Morocco
    • 5.5.5.7 Turkey
    • 5.5.5.8 Rest of Middle East and Africa

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Ranking Analysis
• 6.4 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials (if available), Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.4.1 International Flavors & Fragrances
  • 6.4.2 dsm-firmenich
  • 6.4.3 Kerry Group plc
  • 6.4.4 BASF SE
  • 6.4.5 Associated British Foods plc
  • 6.4.6 Amano Enzyme
  • 6.4.7 Novozymes A/S
  • 6.4.8 Specialty Enzymes & Probiotics
  • 6.4.9 Suntaq International Limited
  • 6.4.10 Biocatalysts Ltd.
  • 6.4.11 Advanced Enzyme Technologies
  • 6.4.12 ENZIQUIM
  • 6.4.13 Nagase America LLC
  • 6.4.14 AST Enzymes
  • 6.4.15 Sunson Industry Group
  • 6.4.16 Enzyme Development Corporation
  • 6.4.17 Antozyme Biotech Pvt Ltd,
  • 6.4.18 NOOR ENZYMES (DWC) LLC
  • 6.4.19 Bioseutica BV
  • 6.4.20 Apex International

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK